- Xiyuan Hospital of China Academy of Chinese Medical Sciences, National Clinical Research Center for Chinese Medicine Cardiology, Beijing 100091, P. R. China;
DONG Guoju,
Email: 13691393589@163.com
Heart failure with preserved ejection fraction (HFpEF) is the main type of heart failure (HF), accounting for more than half of the incidence of HF. However, the etiology, pathogenesis, treatment and prognosis of HFpEF are still not fully understood. Recommendations for HFpEF are in different chapters in the 2022 AHA/ACC/HFSA guideline for the management of heart failure. This paper interpreted the definition, stage, diagnosis, epidemiology, clinical evaluation, stage treatment, acute attack stage, comorbidity management, vulnerable population and research prospect of HFpEF, which aimed to provide the latest thinking in terms of the management of HFpEF for clinicians.
Citation： DONG Guoju. Interpretation of updated key points of heart failure with preserved ejection fraction in the 2022 AHA/ACC/HFSA guideline for the management of heart failure. Chinese Journal of Evidence-Based Medicine, 2022, 22(10): 1117-1124. doi: 10.7507/1672-2531.202205118 Copy
| 1. | Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol, 2017, 70(20): 2476-2486. |
| 2. | Ho JE, Zern EK, Wooster L, et al. Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF definitions. Circulation, 2019, 140(5): 353-365. |
| 3. | Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2013, 62(16): e147-239. |
| 4. | Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation, 2009, 119(14): e391-479. |
| 5. | Madsen BK, Hansen JF, Stokholm KH, et al. Chronic congestive heart failure. description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. Eur Heart J, 1994, 15(3): 303-310. |
| 6. | Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J, 2006, 151(2): 444-450. |
| 7. | Tsao CW, Lyass A, Enserro D, et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail, 2018, 6(8): 678-685. |
| 8. | Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol, 2017, 14(10): 591-602. |
| 9. | Cincin A, Abul Y, Ozben B, et al. Pleural fluid amino-terminal brain natriuretic peptide in patients with pleural effusions. Respir Care, 2013, 58(2): 313-319. |
| 10. | Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol, 2012, 59(11): 998-1005. |
| 11. | Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol, 2014, 64(21): 2281-2293. |
| 12. | Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol, 2013, 62(4): 263-271. |
| 13. | Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiol Pol, 2016, 74(10): 1037-1147. |
| 14. | Erdei T, Smiseth OA, Marino P, et al. A systematic review of diastolic stress tests in heart failure with preserved ejection fraction, with proposals from the EU-FP7 MEDIA study group. Eur J Heart Fail, 2014, 16(12): 1345-1361. |
| 15. | Donal E, Lund LH, Oger E, et al. Value of exercise echocardiography in heart failure with preserved ejection fraction: a substudy from the KaRen study. Eur Heart J Cardiovasc Imaging, 2016, 17(1): 106-113. |
| 16. | Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail, 2010, 3(5): 588-595. |
| 17. | Reddy YNV, Carter RE, Obokata M, et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation, 2018, 138(9): 861-870. |
| 18. | Sepehrvand N, Alemayehu W, Dyck GJB, et al. External validation of the H 2 F-PEF model in diagnosing patients with heart failure and preserved ejection fraction. Circulation, 2019, 139(20): 2377-2379. |
| 19. | Selvaraj S, Myhre PL, Vaduganathan M, et al. Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community. JACC Heart Fail, 2020, 8(8): 640-653. |
| 20. | Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J, 2019, 40(40): 3297-3317. |
| 21. | Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol, 2006, 47(1): 85-90. |
| 22. | Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol, 2004, 43(9): 1590-1595. |
| 23. | Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation, 2006, 113(11): 1424-1433. |
| 24. | Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation, 1997, 95(12): 2660-2667. |
| 25. | Pocock SJ, Ariti CA, McMurray JJ, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J, 2013, 34(19): 1404-1413. |
| 26. | Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J, 2006, 27(1): 65-75. |
| 27. | Wedel H, McMurray JJ, Lindberg M, et al. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail, 2009, 11(3): 281-291. |
| 28. | Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail, 2011, 4(1): 27-35. |
| 29. | Angraal S, Mortazavi BJ, Gupta A, et al. Machine learning prediction of mortality and hospitalization in heart failure with preserved ejection fraction. JACC Heart Fail, 2020, 8(1): 12-21. |
| 30. | Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA, 2013, 310(1): 66-74. |
| 31. | Yancy CW. Sodium restriction in heart failure: too much uncertainty-do the trials. JAMA Intern Med, 2018, 178(12): 1700-1701. |
| 32. | Mahtani KR, Heneghan C, Onakpoya I, et al. Reduced salt intake for heart failure: a systematic review. JAMA Intern Med, 2018, 178(12): 1693-1700. |
| 33. | Machado d'Almeida KS, Rabelo-Silva ER, Souza GC, et al. Aggressive fluid and sodium restriction in decompensated heart failure with preserved ejection fraction: results from a randomized clinical trial. Nutrition, 2018, 54: 111-117. |
| 34. | Kalogeropoulos A, Papadimitriou L, Georgiopoulou VV, et al. Low- versus moderate-sodium diet in patients with recent hospitalization for heart failure: the PROHIBIT (Prevent Adverse Outcomes in Heart Failure by Limiting Sodium) pilot study. Circ Heart Fail, 2020, 13(1): e006389. |
| 35. | Welsh D, Lennie TA, Marcinek R, et al. Low-sodium diet self-management intervention in heart failure: pilot study results. Eur J Cardiovasc Nurs, 2013, 12(1): 87-95. |
| 36. | Davies EJ, Moxham T, Rees K, et al. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. Eur J Heart Fail, 2010, 12(7): 706-715. |
| 37. | Haykowsky MJ, Timmons MP, Kruger C, et al. Meta-analysis of aerobic interval training on exercise capacity and systolic function in patients with heart failure and reduced ejection fractions. Am J Cardiol, 2013, 111(10): 1466-1469. |
| 38. | Santos FV, Chiappa GR, Ramalho SHR, et al. Resistance exercise enhances oxygen uptake without worsening cardiac function in patients with systolic heart failure: a systematic review and meta-analysis. Heart Fail Rev, 2018, 23(1): 73-89. |
| 39. | Taylor RS, Walker S, Smart NA, et al. Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual participant meta-analysis. J Am Coll Cardiol, 2019, 73(12): 1430-1443. |
| 40. | Sagar VA, Davies EJ, Briscoe S, et al. Exercise-based rehabilitation for heart failure: systematic review and meta-analysis. Open Heart, 2015, 2(1): e000163. |
| 41. | Taylor RS, Sagar VA, Davies EJ, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev, 2014, (4): CD003331. |
| 42. | Forman DE, Sanderson BK, Josephson RA, et al. Heart failure as a newly approved diagnosis for cardiac rehabilitation: challenges and opportunities. J Am Coll Cardiol, 2015, 65(24): 2652-2659. |
| 43. | Davies EJ, Moxham T, Rees K, et al. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev, 2010, (4): CD003331. |
| 44. | Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev, 2019, (1): CD003331. |
| 45. | McKelvie RS. Exercise training in patients with heart failure: clinical outcomes, safety, and indications. Heart Fail Rev, 2008, 13(1): 3-11. |
| 46. | Fukuta H, Goto T, Wakami K, et al. Effects of exercise training on cardiac function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Heart Fail Rev, 2019, 24(4): 535-547. |
| 47. | Dieberg G, Ismail H, Giallauria F, et al. Clinical outcomes and cardiovascular responses to exercise training in heart failure patients with preserved ejection fraction: a systematic review and meta-analysis. J Appl Physiol (1985), 2015, 119(6): 726-733. |
| 48. | Kitzman DW, Brubaker PH, Morgan TM, et al. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail, 2010, 3(6): 659-667. |
| 49. | Edelmann F, Gelbrich G, Düngen HD, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol, 2011, 58(17): 1780-1791. |
| 50. | Fujimoto N, Prasad A, Hastings JL, et al. Cardiovascular effects of 1 year of progressive endurance exercise training in patients with heart failure with preserved ejection fraction. Am Heart J, 2012, 164(6): 869-877. |
| 51. | Kitzman DW, Brubaker PH, Herrington DM, et al. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. J Am Coll Cardiol, 2013, 62(7): 584-592. |
| 52. | Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA, 2016, 315(1): 36-46. |
| 53. | Piepoli MF, Davos C, Francis DP, et al. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ, 2004, 328(7433): 189. |
| 54. | Piña IL, Apstein CS, Balady GJ, et al. Exercise and heart failure: a statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation, 2003, 107(8): 1210-1225. |
| 55. | Patterson JH, Adams KF Jr, Applefeld MM, et al. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy, 1994, 14(5): 514-521. |
| 56. | Goebel KM. Six-week study of torsemide in patients with congestive heart failure. Clin Ther, 1993, 15(6): 1051-1059. |
| 57. | Wilson JR, Reichek N, Dunkman WB, et al. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med, 1981, 70(2): 234-239. |
| 58. | Parker JO. The effects of oral ibopamine in patients with mild heart failure-a double blind placebo controlled comparison to furosemide. The Ibopamine Study Group. Int J Cardiol, 1993, 40(3): 221-227. |
| 59. | Richardson A, Bayliss J, Scriven AJ, et al. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet, 1987, 2(8561): 709-711. |
| 60. | Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2021, 143(5): e72-e227. |
| 61. | Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs:meta-analyses of randomized trials. J Hypertens, 2016, 34(10): 1921-1932. |
| 62. | Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA, 2016, 315(24): 2673-2682. |
| 63. | SPRINT Research Group, Wright JT, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med, 2015, 373(22): 2103-2116. |
| 64. | Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med, 2021, 385(16): 1451-1461. |
| 65. | Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med, 2014, 370(15): 1383-1392. |
| 66. | Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation, 2015, 131(1): 34-42. |
| 67. | Solomon SD, Claggett B, Desai AS, et al. Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circ Heart Fail, 2016, 9(3): e002744. |
| 68. | Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, 2003, 362(9386): 777-781. |
| 69. | Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail, 2018, 20(8): 1230-1239. |
| 70. | Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med, 2019, 381(17): 1609-1620. |
| 71. | Solomon SD, Vaduganathan M, L Claggett B, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation, 2020, 141(5): 352-361. |
| 72. | Redfield MM, Anstrom KJ, Levine JA, et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med, 2015, 373(24): 2314-2324. |
| 73. | Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA, 2013, 309(12): 1268-1277. |
| 74. | Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail, 2018, 20(11): 1505-1535. |
| 75. | Greenberg B, Fang J, Mehra M, et al. Advanced heart failure: Trans-Atlantic perspectives on the Heart Failure Association of the European Society of Cardiology position statement. Eur J Heart Fail, 2018, 20(11): 1536-1539. |
| 76. | Albert NM, Nutter B, Forney J, et al. A randomized controlled pilot study of outcomes of strict allowance of fluid therapy in hyponatremic heart failure (SALT-HF). J Card Fail, 2013, 19(1): 1-9. |
| 77. | De Vecchis R, Baldi C, Cioppa C, et al. Effects of limiting fluid intake on clinical and laboratory outcomes in patients with heart failure: results of a meta-analysis of randomized controlled trials. Herz, 2016, 41(1): 63-75. |
| 78. | Expression of concern: normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clin Sci (Lond), 2020, 134(13): 1841. |
| 79. | Al-Kindi SG, Farhoud M, Zacharias M, et al. Left ventricular assist devices or inotropes for decreasing pulmonary vascular resistance in patients with pulmonary hypertension listed for heart transplantation. J Card Fail, 2017, 23(3): 209-215. |
| 80. | Hübner T, Nickel T, Steinbeck G, et al. A single German center experience with intermittent inotropes for patients on the high-urgent heart transplant waiting list. Clin Res Cardiol, 2015, 104(11): 929-934. |
| 81. | Aranda JM, Schofield RS, Pauly DF, et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J, 2003, 145(2): 324-329. |
| 82. | Brozena SC, Twomey C, Goldberg LR, et al. A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. J Heart Lung Transplant, 2004, 23(9): 1082-1086. |
| 83. | Gorodeski EZ, Chu EC, Reese JR, et al. Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. Circ Heart Fail, 2009, 2(4): 320-324. |
| 84. | O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J, 1999, 138(1 Pt 1): 78-86. |
| 85. | Hershberger RE, Nauman D, Walker TL, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail, 2003, 9(3): 180-187. |
| 86. | Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol, 2008, 52(3): 190-199. |
| 87. | Gilstrap LG, Fonarow GC, Desai AS, et al. Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction. J Am Heart Assoc, 2017, 6(2): e004675. |
| 88. | Maisel A, Xue Y, van Veldhuisen DJ, et al. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). Am J Cardiol, 2014, 114(5): 737-742. |
| 89. | Prins KW, Neill JM, Tyler JO, et al. Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis. JACC Heart Fail, 2015, 3(8): 647-653. |
| 90. | Tran RH, Aldemerdash A, Chang P, et al. Guideline-directed medical therapy and survival following hospitalization in patients with heart failure. Pharmacotherapy, 2018, 38(4): 406-416. |
| 91. | Peri-Okonny PA, Mi X, Khariton Y, et al. Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF Registry. JACC Heart Fail, 2019, 7(4): 350-358. |
| 92. | Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA, 2002, 287(12): 1531-1540. |
| 93. | Cioffi G, Stefenelli C, Tarantini L, et al. Hemodynamic response to intensive unloading therapy (furosemide and nitroprusside) in patients >70 years of age with left ventricular systolic dysfunction and decompensated chronic heart failure. Am J Cardiol, 2003, 92(9): 1050-1056. |
| 94. | Elkayam U, Kulick D, McIntosh N, et al. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation, 1987, 76(3): 577-584. |
| 95. | Fung HL, Bauer JA. Mechanisms of nitrate tolerance. Cardiovasc Drugs Ther, 1994, 8(3): 489-499. |
| 96. | Khot UN, Novaro GM, Popović ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med, 2003, 348(18): 1756-1763. |
| 97. | Kozhuharov N, Goudev A, Flores D, et al. Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial. JAMA, 2019, 322(23): 2292-2302. |
| 98. | Peacock WF, Chandra A, Char D, et al. Clevidipine in acute heart failure: results of the a study of blood pressure control in acute heart failure-a pilot study (PRONTO). Am Heart J, 2014, 167(4): 529-536. |
| 99. | Kleber FX, Witt C, Vogel G, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J, 2003, 145(4): 614-621. |
| 100. | Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med, 2013, 368(6): 513-523. |
| 101. | Mebazaa A, Spiro TE, Büller HR, et al. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure. Circulation, 2014, 130(5): 410-418. |
| 102. | Kalogirou F, Forsyth F, Kyriakou M, et al. Heart failure disease management: a systematic review of effectiveness in heart failure with preserved ejection fraction. ESC Heart Fail, 2020, 7(1): 194-212. |
| 103. | Clinical Trials. gov. Dapagliflozin evaluation to improve the LIVEs of patients with preserved ejection fraction heart failure. (DELIVER). Available at: https://clinicaltrials.gov/ct2/show/NCT03619213. |
| 104. | Anker SD, Butler J, Filippatos GS, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail, 2019, 21(10): 1279-1287. |
| 105. | Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation, 2000, 101(10): 1138-1144. |
| 106. | Chatterjee NA, Upadhyay GA, Ellenbogen KA, et al. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis of biventricular vs. right ventricular pacing mode. Eur J Heart Fail, 2012, 14(6): 661-667. |
| 107. | Ho JE, Gona P, Pencina MJ, et al. Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. Eur Heart J, 2012, 33(14): 1734-1741. |
| 108. | Medina-Inojosa JR, Vinnakota S, Garcia M, et al. Role of stress and psychosocial determinants on women's cardiovascular risk and disease development. J Womens Health (Larchmt), 2019, 28(4): 483-489. |
| 109. | Shah AM, Claggett B, Loehr LR, et al. Heart failure stages among older adults in the community: the atherosclerosis risk in communities study. Circulation, 2017, 135(3): 224-240. |
| 110. | Graham G. Disparities in cardiovascular disease risk in the United States. Curr Cardiol Rev, 2015, 11(3): 238-245. |
| 111. | Bahrami H, Kronmal R, Bluemke DA, et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med, 2008, 168(19): 2138-2145. |
| 112. | Lewis EF, Claggett B, Shah AM, et al. Racial differences in characteristics and outcomes of patients with heart failure and preserved ejection fraction in the treatment of preserved cardiac function heart failure trial. Circ Heart Fail, 2018, 11(3): e004457. |
| 113. | Vivo RP, Krim SR, Krim NR, et al. Care and outcomes of Hispanic patients admitted with heart failure with preserved or reduced ejection fraction: findings from get with the guidelines-heart failure. Circ Heart Fail, 2012, 5(2): 167-175. |
- 1. Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol, 2017, 70(20): 2476-2486.
- 2. Ho JE, Zern EK, Wooster L, et al. Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF definitions. Circulation, 2019, 140(5): 353-365.
- 3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2013, 62(16): e147-239.
- 4. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation, 2009, 119(14): e391-479.
- 5. Madsen BK, Hansen JF, Stokholm KH, et al. Chronic congestive heart failure. description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. Eur Heart J, 1994, 15(3): 303-310.
- 6. Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J, 2006, 151(2): 444-450.
- 7. Tsao CW, Lyass A, Enserro D, et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail, 2018, 6(8): 678-685.
- 8. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol, 2017, 14(10): 591-602.
- 9. Cincin A, Abul Y, Ozben B, et al. Pleural fluid amino-terminal brain natriuretic peptide in patients with pleural effusions. Respir Care, 2013, 58(2): 313-319.
- 10. Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol, 2012, 59(11): 998-1005.
- 11. Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol, 2014, 64(21): 2281-2293.
- 12. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol, 2013, 62(4): 263-271.
- 13. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiol Pol, 2016, 74(10): 1037-1147.
- 14. Erdei T, Smiseth OA, Marino P, et al. A systematic review of diastolic stress tests in heart failure with preserved ejection fraction, with proposals from the EU-FP7 MEDIA study group. Eur J Heart Fail, 2014, 16(12): 1345-1361.
- 15. Donal E, Lund LH, Oger E, et al. Value of exercise echocardiography in heart failure with preserved ejection fraction: a substudy from the KaRen study. Eur Heart J Cardiovasc Imaging, 2016, 17(1): 106-113.
- 16. Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail, 2010, 3(5): 588-595.
- 17. Reddy YNV, Carter RE, Obokata M, et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation, 2018, 138(9): 861-870.
- 18. Sepehrvand N, Alemayehu W, Dyck GJB, et al. External validation of the H 2 F-PEF model in diagnosing patients with heart failure and preserved ejection fraction. Circulation, 2019, 139(20): 2377-2379.
- 19. Selvaraj S, Myhre PL, Vaduganathan M, et al. Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community. JACC Heart Fail, 2020, 8(8): 640-653.
- 20. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J, 2019, 40(40): 3297-3317.
- 21. Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol, 2006, 47(1): 85-90.
- 22. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol, 2004, 43(9): 1590-1595.
- 23. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation, 2006, 113(11): 1424-1433.
- 24. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation, 1997, 95(12): 2660-2667.
- 25. Pocock SJ, Ariti CA, McMurray JJ, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J, 2013, 34(19): 1404-1413.
- 26. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J, 2006, 27(1): 65-75.
- 27. Wedel H, McMurray JJ, Lindberg M, et al. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail, 2009, 11(3): 281-291.
- 28. Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail, 2011, 4(1): 27-35.
- 29. Angraal S, Mortazavi BJ, Gupta A, et al. Machine learning prediction of mortality and hospitalization in heart failure with preserved ejection fraction. JACC Heart Fail, 2020, 8(1): 12-21.
- 30. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA, 2013, 310(1): 66-74.
- 31. Yancy CW. Sodium restriction in heart failure: too much uncertainty-do the trials. JAMA Intern Med, 2018, 178(12): 1700-1701.
- 32. Mahtani KR, Heneghan C, Onakpoya I, et al. Reduced salt intake for heart failure: a systematic review. JAMA Intern Med, 2018, 178(12): 1693-1700.
- 33. Machado d'Almeida KS, Rabelo-Silva ER, Souza GC, et al. Aggressive fluid and sodium restriction in decompensated heart failure with preserved ejection fraction: results from a randomized clinical trial. Nutrition, 2018, 54: 111-117.
- 34. Kalogeropoulos A, Papadimitriou L, Georgiopoulou VV, et al. Low- versus moderate-sodium diet in patients with recent hospitalization for heart failure: the PROHIBIT (Prevent Adverse Outcomes in Heart Failure by Limiting Sodium) pilot study. Circ Heart Fail, 2020, 13(1): e006389.
- 35. Welsh D, Lennie TA, Marcinek R, et al. Low-sodium diet self-management intervention in heart failure: pilot study results. Eur J Cardiovasc Nurs, 2013, 12(1): 87-95.
- 36. Davies EJ, Moxham T, Rees K, et al. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. Eur J Heart Fail, 2010, 12(7): 706-715.
- 37. Haykowsky MJ, Timmons MP, Kruger C, et al. Meta-analysis of aerobic interval training on exercise capacity and systolic function in patients with heart failure and reduced ejection fractions. Am J Cardiol, 2013, 111(10): 1466-1469.
- 38. Santos FV, Chiappa GR, Ramalho SHR, et al. Resistance exercise enhances oxygen uptake without worsening cardiac function in patients with systolic heart failure: a systematic review and meta-analysis. Heart Fail Rev, 2018, 23(1): 73-89.
- 39. Taylor RS, Walker S, Smart NA, et al. Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual participant meta-analysis. J Am Coll Cardiol, 2019, 73(12): 1430-1443.
- 40. Sagar VA, Davies EJ, Briscoe S, et al. Exercise-based rehabilitation for heart failure: systematic review and meta-analysis. Open Heart, 2015, 2(1): e000163.
- 41. Taylor RS, Sagar VA, Davies EJ, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev, 2014, (4): CD003331.
- 42. Forman DE, Sanderson BK, Josephson RA, et al. Heart failure as a newly approved diagnosis for cardiac rehabilitation: challenges and opportunities. J Am Coll Cardiol, 2015, 65(24): 2652-2659.
- 43. Davies EJ, Moxham T, Rees K, et al. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev, 2010, (4): CD003331.
- 44. Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev, 2019, (1): CD003331.
- 45. McKelvie RS. Exercise training in patients with heart failure: clinical outcomes, safety, and indications. Heart Fail Rev, 2008, 13(1): 3-11.
- 46. Fukuta H, Goto T, Wakami K, et al. Effects of exercise training on cardiac function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Heart Fail Rev, 2019, 24(4): 535-547.
- 47. Dieberg G, Ismail H, Giallauria F, et al. Clinical outcomes and cardiovascular responses to exercise training in heart failure patients with preserved ejection fraction: a systematic review and meta-analysis. J Appl Physiol (1985), 2015, 119(6): 726-733.
- 48. Kitzman DW, Brubaker PH, Morgan TM, et al. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail, 2010, 3(6): 659-667.
- 49. Edelmann F, Gelbrich G, Düngen HD, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol, 2011, 58(17): 1780-1791.
- 50. Fujimoto N, Prasad A, Hastings JL, et al. Cardiovascular effects of 1 year of progressive endurance exercise training in patients with heart failure with preserved ejection fraction. Am Heart J, 2012, 164(6): 869-877.
- 51. Kitzman DW, Brubaker PH, Herrington DM, et al. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. J Am Coll Cardiol, 2013, 62(7): 584-592.
- 52. Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA, 2016, 315(1): 36-46.
- 53. Piepoli MF, Davos C, Francis DP, et al. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ, 2004, 328(7433): 189.
- 54. Piña IL, Apstein CS, Balady GJ, et al. Exercise and heart failure: a statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation, 2003, 107(8): 1210-1225.
- 55. Patterson JH, Adams KF Jr, Applefeld MM, et al. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy, 1994, 14(5): 514-521.
- 56. Goebel KM. Six-week study of torsemide in patients with congestive heart failure. Clin Ther, 1993, 15(6): 1051-1059.
- 57. Wilson JR, Reichek N, Dunkman WB, et al. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med, 1981, 70(2): 234-239.
- 58. Parker JO. The effects of oral ibopamine in patients with mild heart failure-a double blind placebo controlled comparison to furosemide. The Ibopamine Study Group. Int J Cardiol, 1993, 40(3): 221-227.
- 59. Richardson A, Bayliss J, Scriven AJ, et al. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet, 1987, 2(8561): 709-711.
- 60. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2021, 143(5): e72-e227.
- 61. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs:meta-analyses of randomized trials. J Hypertens, 2016, 34(10): 1921-1932.
- 62. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA, 2016, 315(24): 2673-2682.
- 63. SPRINT Research Group, Wright JT, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med, 2015, 373(22): 2103-2116.
- 64. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med, 2021, 385(16): 1451-1461.
- 65. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med, 2014, 370(15): 1383-1392.
- 66. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation, 2015, 131(1): 34-42.
- 67. Solomon SD, Claggett B, Desai AS, et al. Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circ Heart Fail, 2016, 9(3): e002744.
- 68. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, 2003, 362(9386): 777-781.
- 69. Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail, 2018, 20(8): 1230-1239.
- 70. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med, 2019, 381(17): 1609-1620.
- 71. Solomon SD, Vaduganathan M, L Claggett B, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation, 2020, 141(5): 352-361.
- 72. Redfield MM, Anstrom KJ, Levine JA, et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med, 2015, 373(24): 2314-2324.
- 73. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA, 2013, 309(12): 1268-1277.
- 74. Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail, 2018, 20(11): 1505-1535.
- 75. Greenberg B, Fang J, Mehra M, et al. Advanced heart failure: Trans-Atlantic perspectives on the Heart Failure Association of the European Society of Cardiology position statement. Eur J Heart Fail, 2018, 20(11): 1536-1539.
- 76. Albert NM, Nutter B, Forney J, et al. A randomized controlled pilot study of outcomes of strict allowance of fluid therapy in hyponatremic heart failure (SALT-HF). J Card Fail, 2013, 19(1): 1-9.
- 77. De Vecchis R, Baldi C, Cioppa C, et al. Effects of limiting fluid intake on clinical and laboratory outcomes in patients with heart failure: results of a meta-analysis of randomized controlled trials. Herz, 2016, 41(1): 63-75.
- 78. Expression of concern: normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clin Sci (Lond), 2020, 134(13): 1841.
- 79. Al-Kindi SG, Farhoud M, Zacharias M, et al. Left ventricular assist devices or inotropes for decreasing pulmonary vascular resistance in patients with pulmonary hypertension listed for heart transplantation. J Card Fail, 2017, 23(3): 209-215.
- 80. Hübner T, Nickel T, Steinbeck G, et al. A single German center experience with intermittent inotropes for patients on the high-urgent heart transplant waiting list. Clin Res Cardiol, 2015, 104(11): 929-934.
- 81. Aranda JM, Schofield RS, Pauly DF, et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J, 2003, 145(2): 324-329.
- 82. Brozena SC, Twomey C, Goldberg LR, et al. A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. J Heart Lung Transplant, 2004, 23(9): 1082-1086.
- 83. Gorodeski EZ, Chu EC, Reese JR, et al. Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. Circ Heart Fail, 2009, 2(4): 320-324.
- 84. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J, 1999, 138(1 Pt 1): 78-86.
- 85. Hershberger RE, Nauman D, Walker TL, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail, 2003, 9(3): 180-187.
- 86. Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol, 2008, 52(3): 190-199.
- 87. Gilstrap LG, Fonarow GC, Desai AS, et al. Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction. J Am Heart Assoc, 2017, 6(2): e004675.
- 88. Maisel A, Xue Y, van Veldhuisen DJ, et al. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). Am J Cardiol, 2014, 114(5): 737-742.
- 89. Prins KW, Neill JM, Tyler JO, et al. Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis. JACC Heart Fail, 2015, 3(8): 647-653.
- 90. Tran RH, Aldemerdash A, Chang P, et al. Guideline-directed medical therapy and survival following hospitalization in patients with heart failure. Pharmacotherapy, 2018, 38(4): 406-416.
- 91. Peri-Okonny PA, Mi X, Khariton Y, et al. Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF Registry. JACC Heart Fail, 2019, 7(4): 350-358.
- 92. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA, 2002, 287(12): 1531-1540.
- 93. Cioffi G, Stefenelli C, Tarantini L, et al. Hemodynamic response to intensive unloading therapy (furosemide and nitroprusside) in patients >70 years of age with left ventricular systolic dysfunction and decompensated chronic heart failure. Am J Cardiol, 2003, 92(9): 1050-1056.
- 94. Elkayam U, Kulick D, McIntosh N, et al. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation, 1987, 76(3): 577-584.
- 95. Fung HL, Bauer JA. Mechanisms of nitrate tolerance. Cardiovasc Drugs Ther, 1994, 8(3): 489-499.
- 96. Khot UN, Novaro GM, Popović ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med, 2003, 348(18): 1756-1763.
- 97. Kozhuharov N, Goudev A, Flores D, et al. Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial. JAMA, 2019, 322(23): 2292-2302.
- 98. Peacock WF, Chandra A, Char D, et al. Clevidipine in acute heart failure: results of the a study of blood pressure control in acute heart failure-a pilot study (PRONTO). Am Heart J, 2014, 167(4): 529-536.
- 99. Kleber FX, Witt C, Vogel G, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J, 2003, 145(4): 614-621.
- 100. Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med, 2013, 368(6): 513-523.
- 101. Mebazaa A, Spiro TE, Büller HR, et al. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure. Circulation, 2014, 130(5): 410-418.
- 102. Kalogirou F, Forsyth F, Kyriakou M, et al. Heart failure disease management: a systematic review of effectiveness in heart failure with preserved ejection fraction. ESC Heart Fail, 2020, 7(1): 194-212.
- 103. Clinical Trials. gov. Dapagliflozin evaluation to improve the LIVEs of patients with preserved ejection fraction heart failure. (DELIVER). Available at: https://clinicaltrials.gov/ct2/show/NCT03619213.
- 104. Anker SD, Butler J, Filippatos GS, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail, 2019, 21(10): 1279-1287.
- 105. Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation, 2000, 101(10): 1138-1144.
- 106. Chatterjee NA, Upadhyay GA, Ellenbogen KA, et al. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis of biventricular vs. right ventricular pacing mode. Eur J Heart Fail, 2012, 14(6): 661-667.
- 107. Ho JE, Gona P, Pencina MJ, et al. Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. Eur Heart J, 2012, 33(14): 1734-1741.
- 108. Medina-Inojosa JR, Vinnakota S, Garcia M, et al. Role of stress and psychosocial determinants on women's cardiovascular risk and disease development. J Womens Health (Larchmt), 2019, 28(4): 483-489.
- 109. Shah AM, Claggett B, Loehr LR, et al. Heart failure stages among older adults in the community: the atherosclerosis risk in communities study. Circulation, 2017, 135(3): 224-240.
- 110. Graham G. Disparities in cardiovascular disease risk in the United States. Curr Cardiol Rev, 2015, 11(3): 238-245.
- 111. Bahrami H, Kronmal R, Bluemke DA, et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med, 2008, 168(19): 2138-2145.
- 112. Lewis EF, Claggett B, Shah AM, et al. Racial differences in characteristics and outcomes of patients with heart failure and preserved ejection fraction in the treatment of preserved cardiac function heart failure trial. Circ Heart Fail, 2018, 11(3): e004457.
- 113. Vivo RP, Krim SR, Krim NR, et al. Care and outcomes of Hispanic patients admitted with heart failure with preserved or reduced ejection fraction: findings from get with the guidelines-heart failure. Circ Heart Fail, 2012, 5(2): 167-175.